Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9644705 | 1.00 | CTSK (0.62) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL739719 | 1.00 | CTSK (0.62) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL13263255 | 0.88 | CTSK (0.60) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL29957942 | 0.87 | CTSK (0.59) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL6829984 | 0.86 | CA1 (0.51) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL16564868 | 0.85 | CTSK (0.53) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL3894401 | 0.85 | CTSK (0.60) | CTSKCA1CA2CA7 | |
| SCHEMBL22363059 | 0.85 | CTSK (0.60) | CTSKCA1CA2CA7 | |
| SCHEMBL7433177 | 0.85 | CTSK (0.53) | CTSKCA1CA2CA7CTSL | |
| SCHEMBL6786634 | 0.85 | CTSK (0.53) | CTSKCA1CA2CA7CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | claimed |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2017-09-14 | — | — | US | claimed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2016-02-25 | — | — | US | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| EP-1194449-B1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MED RES FOUND (US) | 2010-09-22 | — | — | EP | claimed |
| US-7678760-B2 | Inhibitors of Memapsin 2 and use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-16 | — | — | US | claimed |
| US-20080021196-A1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-01-24 | — | — | US | claimed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| CN-112368263-B | Dipeptidyl ketoamide m-methoxyphenyl derivative and application thereof | 兰德施泰纳根梅德公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| EP-0376012-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0369391-A2 | N-substituted amides | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4886914-A | REACTING N,O-DIMETHYLHYDROXYLAMINE WITH BLOCKED AMINO ACID ESTER AND REDUCING | SANOFI (FR) | 1989-12-12 | — | — | US | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CTSK 1682/4885CA1 477/4885CA2 309/4885 |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | CTSK 4156/4885CA1 4464/4885CA2 4395/4885 |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | CTSK 3267/4885CA1 4256/4885CA2 3436/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | CTSK 2553/4885CA1 1530/4885CA2 1672/4885 |
| US-20080021196-A1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | PSEN2, APP, ANPEP | CTSK 2847/4885CA1 2083/4885CA2 2733/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | CTSK 4156/4885CA1 4464/4885CA2 4395/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | CTSK 2078/4885CA1 1094/4885CA2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.